The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of neoadjuvant (neo) palbociclib (Palbo) plus anastrozole (ana) in endocrine resistant clinical stage 2/3 estrogen receptor positive and HER2 negative (ER+ HER2-) breast cancer (BC).
 
Nusayba Ali Bagegni
No Relationships to Disclose
 
Feng Gao
No Relationships to Disclose
 
Matthew P. Goetz
Consulting or Advisory Role - Lilly (Inst)
Research Funding - Lilly; Pfizer
 
Donald W. Northfelt
No Relationships to Disclose
 
Andres Forero-Torres
Speakers' Bureau - Seagen
Research Funding - Daiichi Sankyo (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Novartis (Inst); Oncothyreon (Inst); Pfizer (Inst); Seagen (Inst); Syndax (Inst); TRACON Pharma (Inst)
 
Jill Anderson
No Relationships to Disclose
 
Kiran R. Vij
No Relationships to Disclose
 
Souzan Sanati
No Relationships to Disclose
 
Matthew J Ellis
Consulting or Advisory Role - Pfizer
 
Cynthia X. Ma
Consulting or Advisory Role - AstraZeneca; Merck; Novartis; Novartis; Pfizer; Pfizer; Puma Biotechnology; Roche
Research Funding - Eisai (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Novartis; Novartis; Pfizer; pfizer; Roche